SEC Form D private-offering filing

NurExone Biologic Inc.

A new SEC Form D private-offering notice from Technion City, Haifa, a $441,779 filer-stated offering target in Biotech. The source filing is one click away.

NurExone Biologic Inc. site↗ Verified via SEC Form D

Develops exosome based nanodrug therapies for central nervous system injuries, including its lead candidate ExoPTEN for acute spinal cord injury.

Filed 2026-07-02Filed to raise $441,779First money in 2026-06-30Raised so far $441,779HQ (as filed) Technion City, HaifaSector Biotech Stage (inferred) Pre-seedCall status Needs classification
Source linked the Form D on EDGAR↗Website verified nurexone.com↗Named in the filing 6 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.